Gold prices edge higher with focus on Ukraine-Russia, Jackson Hole
BioHarvest Sciences Inc. (formerly known as Canna-V-Cell Sciences Inc. and Midnight Star Ventures Corp.), a pharmaceutical preparations company, has submitted its unaudited interim condensed consolidated financial statements for the first quarter ended March 31, 2025. The report, filed today with the United States Securities and Exchange Commission, provides a snapshot of the company’s financial position.
The filing, identified by commission file number 001-42389, includes the financial statements for the three months leading up to March 31, 2025, as well as management’s discussion and analysis of the financial condition and results of operations for the same period. Additionally, certifications of interim filings by the CEO and CFO were submitted as part of the filing.
BioHarvest Sciences, headquartered in Vancouver, British Columbia, operates under the pharmaceutical preparations industry classification. The company has not provided a translation of its name into English, suggesting that BioHarvest Sciences Inc. is the name used in both domestic and international markets.
The report was signed by David Ryan, Vice-President, Investor Relations & Secretary of BioHarvest Sciences Inc., indicating the company’s compliance with the Securities Exchange Act of 1934 and the authorization of the report by the registrant.
This financial disclosure provides investors and stakeholders with relevant information about BioHarvest Sciences’ financial health and business performance during the first quarter of 2025. The company’s commitment to transparency is evident in the timely filing of its financial documents, ensuring that all interested parties have access to important financial data.
The information presented in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.